Urofollitropin
Also known as: Bravelle, Fertinex, Fostimon, Metrodin, uFSH, Urinary FSH, Urofollitropin
Source Urofollitropin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Urofollitropin is a purified urinary‑derived FSH used to induce controlled ovarian stimulation in women undergoing assisted reproductive techniques.
Mechanism of Action
Binds the FSH receptor on ovarian granulosa cells, stimulating follicular growth and estradiol synthesis.
Routes of Administration
Goals & Uses
- Spermatogenesis induction in malesMale InfertilityModerate
- Follicular monitoring and maturationReproductive EndocrinologyHigh
- Controlled ovarian stimulationReproductiveHigh
- Ovulation inductionReproductive EndocrinologyHigh
- Controlled ovarian stimulation for ART/IVFReproductive EndocrinologyHigh
Contraindications
- Untreated ovarian cysts or severe PCOSGynecologicModerate
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Primary ovarian failure / high baseline FSHEndocrineHigh
- Hormone-sensitive tumors (e.g., ovarian, uterine, breast)OncologyHigh
- Ovarian cysts or enlarged ovaries of unknown etiologyGynecologyModerate
- Uncontrolled thyroid or adrenal dysfunctionEndocrinologyHigh
- Estrogen‑dependent neoplasmsOncologyHigh
- Hypersensitivity to FSH preparationsAllergy/ImmunologyHigh
Adverse Effects
- Injection site reactionsLocalCommon
- Multiple gestationReproductiveUncommon
- Hypersensitivity/anaphylaxisImmunologicalRare
- HeadacheNeurologicCommonPain in the head or upper neck
- Abdominal bloating and discomfortGastrointestinalCommon
- Multiple pregnancyReproductiveRare
- Injection site reactionLocalCommonRedness, swelling, itching, bruising, or pain at the injection site
- Ovarian hyperstimulation syndrome (OHSS)ReproductiveCommon
Drug Interactions
- Oral contraceptivesModerateDelayed gastric emptying may affect absorption timing
- Human Chorionic Gonadotropin (hCG)Low
- GnRH antagonists (e.g., cetrorelix, ganirelix)Low
- GnRH agonists/antagonistsModerate
- Clomiphene citrateLow
- GnRH agonists (e.g., leuprolide)Low
Population Constraints
- Women with poor ovarian reserveReproductive EndocrinologyRelative
- Women with PCOSReproductive EndocrinologyRelative
- Pediatric patientsAgeAbsolute
- Women with uncontrolled thyroid diseaseEndocrineRelative
- MenSexAbsolute
- Postmenopausal womenReproductive StatusAbsolute
Regulatory Status
- European UnionApprovedApproved: infertility – assisted reproduction
- United StatesApprovedApproved: infertility – controlled ovarian stimulationMarketed as Bravelle, Fertinex.
- United KingdomApprovedApproved: infertility – ovarian stimulation
Extracted from pooled post‑menopausal human urine; approved in multiple jurisdictions for infertility treatment; administered by injection.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Urofollitropin?
Urofollitropin is a purified urinary‑derived FSH used to induce controlled ovarian stimulation in women undergoing assisted reproductive techniques.
What is Urofollitropin used for?
Urofollitropin is educationally associated with: Spermatogenesis induction in males, Follicular monitoring and maturation, Controlled ovarian stimulation, Ovulation induction, Controlled ovarian stimulation for ART/IVF. Educational only — not medical advice.
How is Urofollitropin administered?
Recorded routes of administration: Intramuscular, Subcutaneous.
What are the potential side effects of Urofollitropin?
Reported adverse effects include: Injection site reactions, Multiple gestation, Hypersensitivity/anaphylaxis, Headache, Abdominal bloating and discomfort, Multiple pregnancy, Injection site reaction, Ovarian hyperstimulation syndrome (OHSS). This list is not exhaustive — consult a qualified clinician.
Who should avoid Urofollitropin?
Recorded contraindications: Untreated ovarian cysts or severe PCOS, Pregnancy, Primary ovarian failure / high baseline FSH, Hormone-sensitive tumors (e.g., ovarian, uterine, breast), Ovarian cysts or enlarged ovaries of unknown etiology, Uncontrolled thyroid or adrenal dysfunction, Estrogen‑dependent neoplasms, Hypersensitivity to FSH preparations. Consult a qualified clinician before use.